Background: The SAPIEN 3 transcatheter heart valve with the low profile Commander transfemoral and Certitude transthoracic delivery systems (Edwards Lifesciences, CA) incorporate features intended to facilitate accurate positioning and improve paravalvular sealing. We review the initial clinical experience with this device. Methods: SAPIEN 3 valves were implanted in 26 patients (age 79.2AE9.3 years, 88.5% male, STS score 6.1AE3.6). Results: Device size was 26mm in 88.5%, 29mm in 11.5%. Valve positioning was accurate in all cases, with no moderate or severe paravalvular leaks. Mean aortic valve gradient decreased from 39.6AE15.7mmHg to 12.4AE4.7mmHg and mean aortic valve area increased from 0.67AE0.16cm2 to 1.62AE0.35cm2 (p<0.001). Major vascular complications occurred in 3.8%, major/life-threatening bleeding rate in 7.7%, and there were no stroke events. Hospital discharge was a median of 3 days after the procedure. Survival at 30 days was 96.2% with 92.3% of survivors in NYHA functional class I or II. Conclusions: Early outcomes with the SAPIEN 3 THV were excellent with improved device positioning and reduced post procedural regurgitation. Longer follow-up of a larger group of patients is needed to validate these findings. Background: Balloon aortic valvuloplasty (BAV) is occasionally a bridge for optimizing transcatheter aortic valve replacement outcomes. This study examined whether BAV improves renal insufficiency in these high-risk patients. Methods: Our 320 pt BAV database was queried for pts with stage-4 chronic kidney disease (CKD 4 , CrCl) <30 ml/min) and stage-3 (CKD 3 , CrCl 30-59 ml/min). CrCl was determined using the Cockcroft-Gault equation. Demographics including risk factors, intraprocedural hemodynamics, pre and post BAV echocardiographic findings, periprocedural fluids, medication regimens, and pre and post BAV CrCl (DCrCl) were compared for differences between the two groups (gp). Successful BAV was defined as !30% increase in echocardiographic AVA. Results: 81 pts were identified, 15 in the CKD 4 gp (age 85AE6.2), and 66 in the CKD 3 gp (83.7AE7.5). Baseline CrCl in CKD 4 was 24.4AE4.3 ml/min, and in CKD 3 pts was 46.3AE9.0 ml/min. The mean post BAV improvement in CrCl for the CKD 4 pts was 9.6AE13.9 ml/min and CKD 3 pts was -1.8AE11.2 ml/min (p¼0.0011) respectively. There was a significant association between age and CrCl improvement across all pts. The odds ratio of significant improvement in CKD 4 pts was age dependent up to 82 years of age. The mean follow-up time was 83.9AE7.2 days. Conclusions: Patients with CKD and aortic stenosis undergoing BAV experience a modest improvement in CrCl. Improvement was associated with more advanced CKD and younger age.
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Intentionally Underexpanding Balloon-expandable Transcatheter Aortic Valves: Proof of concept and clinical implications Background: Oversizing of balloon-expandable transcatheter heart valves (THVs) during transcatheter aortic valve replacement (TAVR) is recommended to reduce paravalvular regurgitation. However excessive oversizing may be associated with a risk of annular injury. Methods: Patients (n¼43) who underwent TAVR with an intentionally underexpanded balloon expandable THV were enrolled in this study. In patients where the nominal THV cross sectional area exceeded the CT annular area by >20% (or >15% with adverse root features) the deployment balloon was intentionally underfilled by 5-15%. Study patients were compared to consecutive control patients, who had nominally filled THV deployment balloons (n¼87). All patients underwent pre and post procedural CT imaging as well as transthoracic and transesophageal echocardiography to assess THV stent geometry, expansion, eccentricity and hemodynamics. Results: Among the study group, the THV balloon was underfilled by 1, 2, 3, and 4 ml in 7(16.3%), 24(55.8%), 10(23.3%), and 2(4.7%) patients, respectively. On transthoracic echocardiogram, post procedure THV area was 1.62AE0.38 cm2 in the study group and 1.66AE0.41 cm2 in the control group(p¼0.602). Mean gradient across the THV was 11.2AE4.0 mmHg and 10.6AE3.9 mmHg in study and control groups, respectively (p¼0.411). Paravalvular regurgitation was >mild in 1 patient (3.0%) in the study group and 6(6.9%) patients in the control group (p¼0.261). Transvalvular regurgitation was not observed in either group. In-hospital complication rates were similar. THV expansion at the inflow was 85.2AE7.2% versus 102.5AE6.2%(p<0.001), at the mid-portion 88.1AE7.3% versus 102.4AE6.3% (p<0.001) and at the outflow 91.5AE7.2% versus 102.8AE6.0% (p<0.001), in study versus control groups respectively. Conclusions: Intentionally underexpanding balloon-expandable THVs as part of a strategy intended to reduce paravalvular regurgitation and annular injury did not appear to adversely affect procedural clinical outcomes, THV gradients, or THV areas. The impact of underexpansion of THVs on durability and late outcomes remains to be determined. DCrCl (baseline to follow-up) (ml/min), meanAESD 9.6AE13.9 -1.8AE11.2 0.0011
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